Last updated: 07/29/2020 14:10:05

Dose escalating study of CCI15106 inhalation capsules in healthy subjects and moderate chronic obstructive pulmonary disease (COPD) patients

Request patient level data
GSK study ID
202031
See study documents
Clinicaltrials.gov ID
NCT03243760
EudraCT ID
2015-003960-35
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A double-blind (sponsor unblind), randomized, placebo-controlled, single and repeat escalating dose study to investigate the safety, tolerability, and pharmacokinetics of CCI15106 capsules for inhalation in healthy subjects and patients with moderate chronic obstructive pulmonary disease (COPD)
Trial description: This study will be the first administration of CCI15106 capsules for inhalation to humans. The primary objective of the study is to investigate the safety and tolerability of single and repeat escalating doses of CCI15106 in healthy subjects and patients with moderate chronic obstructive pulmonary disease (COPD). The intention of this study is to provide sufficient confidence in the safety of the molecule delivered by inhalation to inform progression to further repeat dose and proof of concept studies.
This will be a three-part study. Part 1 will investigate single ascending doses and Part 2 repeat ascending doses in healthy subjects. In Part 3, a single dose will be administered to patients with moderate COPD.
There will be screening period of up to 30 days. The treatment period will be 3 days for Parts 1 and 3 and 16 days for Part 2. Follow-up will be performed within 30 days after the last dose.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Allocation:
Randomized
Primary outcomes:

Part 1: Number of participants with adverse events (AE)

Timeframe: Up to 33 days

Part 2: Number of participants with AE

Timeframe: Up to 46 days

Part 3: Number of participants with AE

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal clinical hematology test findings

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal clinical hematology test findings

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal clinical hematology test findings

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal clinical chemistry test findings

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal clinical chemistry test findings

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal clinical chemistry test findings

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal urine analysis test findings

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal urine analysis test findings

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal urine analysis test findings

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal findings of body temperature

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal findings of body temperature

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal findings of body temperature

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal blood pressure values

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal blood pressure values

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal blood pressure values

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal pulse rate values

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal pulse rate values

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal pulse rate values

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal respiratory rate values

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal respiratory rate values

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal respiratory rate values

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal electrocardiogram (ECG) findings

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal ECG findings

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal ECG findings

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal Telemetry findings

Timeframe: Up to 33 days

Part 2: Number of subjects with abnormal telemetry findings

Timeframe: Up to 46 days

Part 3: Number of subjects with abnormal telemetry findings

Timeframe: Up to 33 days

Part 1: Number of subjects with abnormal spirometry findings

Timeframe: Up to 4 hour post-dose

Part 2: Number of subjects with abnormal spirometry findings

Timeframe: Up to 14 days

Part 3: Number of subjects with abnormal spirometry findings

Timeframe: Up to 4 hour post dose

Part 1: Area under the curve (AUC) from time zero to infinity (AUC[0-inf] following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 3: AUC[0-inf] following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 1: AUC from time zero to the time of last quantifiable concentration (AUC[0-last]) following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 3: AUC[0-last] following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 1: Maximum plasma concentration (Cmax) following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 2: Cmax following repeat dose administration of CCI15106

Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12 hours post dose on Day 1 and 14; Pre-dose on Day 2-12 and on follow-up

Part 3: Cmax following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 1: time of maximum concentration (Tmax) following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 2: Tmax following repeat dose administration of CCI15106

Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12 hours post dose on Day 1 and 14; Pre-dose on Day 2-12 and on follow-up

Part 3: Tmax following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 1: Elimination half life (T1/2) following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 3: T1/2 following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 1: Clearance (CL/F) following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

part 3: CL/F following single dose administration of CCI15106

Timeframe: Pre dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 24 hour post-dose and on follow-up

Part 2: AUC from time zero to end of dosing interval (AUC[0-tau]) following repeat dose administration of CCI15106

Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12 hours post dose on Day 1 and 14; Pre-dose on Day 2-12 and on follow-up

Secondary outcomes:

Part 1 Concentrations of CCI15106 in ELF and BAL cell pellet

Timeframe: Up to 2 hour post-dose

Part 2: Concentrations of CCI15106 in ELF and BAL cell pellet

Timeframe: Up to 13 days

Part 1: Number of medical device incidents

Timeframe: Day 1

Part 2: Number of medical device incidents

Timeframe: Up to 14 days

Part 3: Number of medical device incidents

Timeframe: Day 1

Interventions:
  • Drug: CCI15106 7.5 mg capsule
  • Drug: Placebo
  • Drug: Placebo-2
    • Enrollment:
    60
    Primary completion date:
    2016-20-07
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Etienne Dumont, Amanda Oliver, Chris Ioannou, Julia Billiard, Jeremy Dennison, Frans Van Den Berg, Shuying Yang, Vijaya Chandrasekaran, Graeme Young, Anirban Lahiry, Dave Starbuck, Andy Harrell, Alex Georgiou, Nathalie Hopchet, Andy Gillies, Steve Baker .Phase I studies evaluating safety, tolerability, and pharmacokinetics of an inhaled dry-powder formulation containing ribavirin in healthy participants and those with COPD .Antimicrob Agents Chemother.2020;64(5) DOI: 10.1128/AAC.02267-19 PMID: 32071044
    Medical condition
    Pulmonary Disease, Chronic Obstructive
    Product
    ribavirin
    Collaborators
    Not applicable
    Study date(s)
    February 2016 to August 2016
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 75 years
    Accepts healthy volunteers
    Yes
    • For Healthy Subjects
    • Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
    • For Healthy Subjects
    • Male partners of women who are pregnant or lactating
    Inclusion and exclusion criteria
    Inclusion criteria:
    • For Healthy Subjects
    • Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
    • Healthy as determined by the investigator.
    • Body weight >= 50 kilogram (kg) for males and 45 kg for females and body mass index (BMI) within the range 19 – 31 kg/meter square (m^2) (inclusive)
    • Male or Female: Male subjects with female partners of child bearing potential must comply with the contraception requirements as specified in protocol. A female subject is eligible to participate if she is of non-reproductive potential.
    • Capable of giving signed informed consent. For COPD Patients
    • Between 40 and 75 years of age inclusive, at the time of signing the informed consent.
    • Diagnosed with moderate COPD (GOLD class II) by a qualified physician as defined by the GOLD guidelines (http://www.goldcopd.org/).
    • The subject has spirometry at screening, showing: a) post-bronchodilator forced expiratory volume in 1 second (FEV1)>=50% and <80% predicted normal; b) post-bronchodilator FEV1/ forced vital capacity (FVC)<0.7.
    • Subject is a smoker or an ex-smoker.
    • Body weight >= 45 kg and BMI within the range 17 – 32 kg/m^2 (inclusive).
    • Male or Female: Male subjects with female partners of child bearing potential must comply with the contraception requirements as specified in protocol. A female subject is eligible to participate if she is of non-reproductive potential.
    • Capable of giving signed informed consent.
    Exclusion criteria:
    • For Healthy Subjects
    • Male partners of women who are pregnant or lactating
    • Alanine transaminase (ALT) and/or bilirubin >1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
    • QT interval corrected for heart rate (QTc )> 450 millisecond (msec).
    • Heart rate: <40 and >100 beats per minute (bpm) for males and <50 and >100 bpm for females, PR Interval: <120 and >220 msec, QRS duration: <70 and >120 msec, QTcF interval: >450 msec
    • Any clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions.
    • Unable to refrain from prescription or non-prescription drugs
    • History of regular alcohol consumption within 3 months of the study
    • Breath test indicative of smoking at day -1
    • History of sensitivity to any of the study medications
    • For cohorts that will undergo BAL, contraindications to bronchoalveolar lavage
    • Documented lactose allergy/intolerance for cohorts with lactose placebo if they are used in the study.
    • Hemoglobin (Hgb) below the lower level of the normal range with one repeat testing allowed, or known hemoglobinopathies.
    • Known severe hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis, and erythema multiforme.
    • Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
    • A positive pre-study drug/alcohol screen.
    • A positive test for human immunodeficiency virus (HIV) antibody.
    • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 3 month period.
    • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
    • Exposure to more than four new chemical entities within 12 months prior to the first dosing day. For COPD Patients
    • Male partners of women who are pregnant or lactating.
    • ALT and/or bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
    • QTc > 450 msec or QTc > 480 msec in subjects with Bundle Branch Block.
    • Heart rate: <40 and >100 bpm for males and <50 and >100 bpm for females, PR Interval: <120 and >220 msec, QRS duration: <70 and >120 msec, QTcF interval: >450 msec
    • Subject has poorly controlled COPD as defined in protocol
    • History of an upper or lower respiratory tract infection requiring antibiotics in the 4 weeks prior to screening.
    • Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that might, in the opinion of the Investigator, compromise the safety of the subject or affect the interpretation of the results.
    • Subjects who have past or current medical conditions or diseases that are not well controlled.
    • Subjects are not allowed to take oral corticosteroids from 4 weeks prior to screening and for the duration of the study.
    • Patients taking medications for any chronic conditions have to be on stable doses for 4 weeks prior to screening and until after completion of the treatment period. This includes COPD maintenance therapies (e.g. inhaled corticosteroids, long-acting beta-agonists, long-acting muscarinic agonists).
    • Didanosine and azathioprine are not allowed.
    • Use of short-acting inhaled bronchodilators is allowed, but patients must be able to discontinue their medications twice during the study.
    • Use of long-acting bronchodilators is allowed, but patients must be able to modify the schedule of their medications twice during the study.
    • Unable to refrain from smoking for 2 hour (h) prior to dosing and until all assessments are complete for 4 h after dosing and also for 1 h prior to any vital signs and ECG assessments.
    • History of regular alcohol consumption within 3 months of the study
    • History of sensitivity to any of the study medications.
    • Documented lactose allergy/intolerance
    • Impaired renal function (creatinine clearance < 50 mL/ minute).
    • Known severe hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis, and erythema multiforme.
    • Hgb below the lower level of the normal range with one repeat testing allowed or known hemoglobinopathies.
    • Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
    • A positive pre-study drug/alcohol screen.
    • A positive test for HIV antibody.
    • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 3 months.
    • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
    • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    London, United Kingdom, NW10 7EW
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Other
    Actual primary completion date
    2016-20-07
    Actual study completion date
    2016-20-08

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website